Intensity Therapeutics, Inc. Common stock (INTS) Earnings Date, Estimates & Call Transcripts → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free INTS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesOwnershipShort InterestSocial Media Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueINTS Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.INTS Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> Intensity Therapeutics, Inc. Common stock Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript11/13/2023Q3 2023-($0.17)($0.17)($0.17)--8/14/2023Q2 2023-($1.43)($1.43)($1.43)-- Intensity Therapeutics, Inc. Common stock Earnings - Frequently Asked Questions How much profit does Intensity Therapeutics, Inc. Common stock generate each year? Intensity Therapeutics, Inc. Common stock (NASDAQ:INTS) has a recorded net income of -$10.54 million. INTS has generated $0.00 earnings per share over the last four quarters. More Earnings Resources from MarketBeat Related Companies: Ikena Oncology Earnings Results Dyadic International Earnings Results Aligos Therapeutics Earnings Results Turnstone Biologics Earnings Results Entera Bio Earnings Results Cidara Therapeutics Earnings Results Instil Bio Earnings Results Elutia Earnings Results Quince Therapeutics Earnings Results Cognition Therapeutics Earnings Results Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future OutlookCSX Co.: The Railroad Powering Ahead with an Earnings Beat What's Driving Tesla Lower Ahead of its Earnings?Blackrock vs. State Street: Earnings in a Volatile MarketWhat to Expect From the Q1 Earnings Reporting SeasonLululemon Stock Implodes Post Earnings, Guidance Muted This page (NASDAQ:INTS) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyProtect Your Bank Account Before It’s Too LateWeiss RatingsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intensity Therapeutics, Inc. Common stock Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
